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Abstract. Background: Pituitary adenoma is the most benign tumor of hormone-producing 
cells in the anterior pituitary gland, ranging from 10%-15% of the entire intracranial mass. 
The prevalence of pituitary adenoma is still unknown. Epidemiological studies are still very 
limited and external factors such as the enforcement of diagnosis, disease distribution, and 
others resulting in limited epidemiological, postmortem, and radiological study data. 
Pituitary adenoma is often asymptomatic or asymptomatic and is not typical so the diagnosis 
is too late. Clinical manifestations of adenohipofisis: hypersecretion syndrome or hormonal 
deficiency; neurological manifestations due to the effects of an enlarged mass with imaging 
modalities. Case presentation: A 49-year-old man was referred to hospital with complaints 
of chronic headaches and blurred vision. Physical examination is generally within normal 
limits. Previous history of the disease or treatment is also not specific. MRI of the brain shows 
hyperintens lesions in the supracellular or sellar area. Hormone test findings also show 
hypocortisolism and hyperprolactinemia. Conclusion: Conservative treatment is carried out 
with a hormone deficiency subsite. 
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Abstrak. Latar belakang: Adenoma hipofisis merupakan tumor jinak tersering dari sel 
penghasil hormon di kelenjar hipofisis anterior, berkisar 10%-15% dari seluruh massa 
intrakranial. Prevalensi dari adenoma hipofisis ini masih belum diketahui secara pasti. Studi 
epidemiologis masih sangat terbatas dan bias oleh faktor eksternal seperti penegakan 
diagnosis, persebaran penyakit, dan lain-lain menyebabkan terbatasnya data studi 
epidemiologis, postmortem, dan radiologis. Adenoma hipofisis ini sering kali bersifat 
asimptomatik atau bergejala tidak khas sehingga diagnosis pun terlambat ditegakkan. 
Manifestasi adenohipofisis secara klinis ada tiga: sindrom hipersekresi atau defisiensi 
hormon; manifestasi neurologis akibat efek massa yang membesar dengan modalitas 
pencitraan. Presentasi kasus: Seorang laki-laki berumur 49 tahun dirujuk ke rumah sakit 
dengan keluhan sakit kepala kronik dan pandangan kabur. Pemeriksaan fisik secara umum 
dalam batas normal. Riwayat penyakit sebelumnya atau pengobatan juga tidak spesifik. MRI 
otak menunjukkan lesi hiperintens pada area suprasellar/sellar. Temuan pemeriksaan 
hormon juga menunjukkan hipokortisolisme dan hiperprolaktinemia. Kesimpulan: 
Perawatan konservatif dilakukan dengan subsitusi kekurangan hormon. 
Kata Kunci: Adenoma pituitari; hiperprolaktism; hipokortisolism 
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1  Introduction 
Pituitary adenomas are the most common type and benign tumors arising from hormone 
expressing cells in the anterior pituitary gland. They account for 10% to 15% of all intracranial 
masses [1-4]. Pituitary adenomas are broadly categorised as "functioning" (hormone-secreting) 
and "non-functioning" (non-secreting) adenomas. They can be further classified by cell type and 
size [1,3,5]. Pituitary adenomas present clinically in three ways: syndromes of hormone 
hypersecretion or deficiency; neurologic manifestations form the mass effect of an expanding 
gland; or an incidental finding on imaging done for an unrelated issue [1,3,6]. Pituitary adenomas 
are often clinically silent or manifest with non-specific symptoms, which can lead to a delayed 
diagnosis. Clinical practice shows that both functioning and non-functioning pituitary adenomas 
are likely missed initially due to non-specific symptoms [5].  
Pituitary apoplexy occurs in 0.6-10% of pituitary adenoma, especially non-functioning pituitary 
adenoma. It evolves in hours to days and is considered potentially fatal emergency occurring in 
these patients with pituitary adenoma The precise pathophysiology is not completely understood 
and remains uncertain, could be associated with trauma, iatrogenic, hypertension, systemic 
surgeries, and dynamic pituitary function test [7-9]. This case presentation demonstrates diagnosis 
with pituitary apoplexy resulting from pituitary macroadenoma based on clinical manifestation, 
laboratory assay, radiographic imaging perspectives and conservative management. 
2 Case Illustration 
A 49-years old man, was refered to the H. Adam Malik Public Hospital on October 15th, 2020 
with a chief complaint of headache. The patient admitted that he has experienced a headache since 
4 months ago and worsened for 1 latest month. Pain is reduced by analgetics use and waxed as if 
he didn't take medication anymore, it has been getting worse and uncomfortable over days, 
making it difficult to do daily activities. The patient also complained of blurred vision since 3 
months ago, worsened since this last month. It was especially delineated as disturbances in lateral 
view of the left and right eyes, making it difficult to read small letters in newspapers, no 
improvement reported by altering reading distance. Weight loss was admitted 1 month ago with 
approximately 10 kg accompanied by anorexia. Nausea, vomiting, and swallowing difficulties 
were absent. Behavior alteration has been recognized since 2 years ago to become more 
unresponsive to external stimuli, depicted as feeble, more irritable, and anhedonia. Sexual 
problems were admitted for 2 years. Defecating and urinating were within normal limits. History 
of fever, shortness of breath, and breast enlargement was denied.  
The patient was initially diagnosed with pituitary macroadenoma in September 2020. He has lived 
with his wife and son. Socioeconomic status was in the lower range, previously worked as a 
journalist and has not worked for 2 years. There are no similar symptoms experienced by the 
patient's family. 
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The patient appeared to be moderately ill, fully alert, BMI: 27.7 kg/m2 (Obese I). BP 120/80 
mmHg, pulse rate 90 beats/minute, respiration rate 18 times/minute, temperature 36.70C. General 
physical examination revealed no abnormalities. 
Table 1 Clinical Pathology Laboratory Results October 21st 2020 (Pre-Treatment) 
 
Full Blood Count Unit Result Reference 
Hemoglobin (HGB) g/dL 13.2 13-18 
Erythrocyte (RBC) Juta/µL 4.23 4.50-6.50 
Leukocyte (WBC) /µL 5,760 4,000-11,000 
Hematocrit % 38 39-54 
Thrombocyte (PLT) /µL 158,000 150,000-450,000 
MCV fL 91 81-99 
MCH pg 31.2 27.0-31.0 
MCHC g/dL 34.5 31.0-37.0 
RDW % 13.6 11.5-14.5 
MPV fL 10.7 6.5-9.5 
PCT % 0.170 0.100-0.500 
PDW % 11.9 10.0-18.0 
LED mm/1 jam 10 0-10 
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U/L 89 0-55 
Carbohydrate Metabolism 
























• Natrium (Na) 
• Potassium (K) 





















Table 2 Clinical Pathology Laboratory Results (Before Therapy) 
Hormone Assay Unit Result Reference 
Cortisol µg/dL 1.3 3.7-19.4 
Prolactin ng/mL 53.43 2.58-18.12 
TSH µIU/mL 0.76 0.35-4.94 
FreeT4 ng/dL 0.68 0.7-1.48 
 
On November 4th 2020, hormone assay was re-monitored with the following results. 
Table 3 Results of Clinical Pathology Laboratory November 4th, 2020 
(Post Euthyrax 1x50mcg and Prednisone 10-0-5mg Treatment) 
Hormone Assay Unit Outcome Reference 
Cortisol µg/dL 5.1 3.7-19.4 
Prolactin ng/mL 48.13 2.58-18.12 
TSH µIU/mL 0.93 0.35-4.94 
FreeT4 ng/dL 0.86 0.7-1.48 
 
On September 14th 2020, MRI brain T1W scan revealed hyperintense lesions in the 
sella/suprasellar area, dimension ±3.3x2.9x2.5 cm with a fluid-fluid level (snowman shape), 
pressing optic chiasm superiorly. T2W and FLAIR appeared hyperintense. There were also 
hyperintensity lesion in the left and right periventricular areas of white matter. At T2 GRE, the 
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susceptibility effect appeared on the dependent part of the sella/suprasellar lesion. No mass effect 
and midline shift. Cortical sulci and ventricular system were normal. Normal brain stem signals 
appeared. Normal left and right IAC. There was no abnormal enhancement of the lesion in the 
sella/suprasellar region. The right and left cavernous sinuses are normal. 
Patient was diagnosed with putuitary macroadenoma suspect apoplexy with secondary 
hypothyroid, hypocortisolism, and hyperprolactinemia. Differential diagnosis includes pituitary 
macroadenoma suspect apoplexy due to craniopharyngioma or metastatic tumor, tersier 
hypothyroid, and prolactinoma. 
3 Discussion 
Pituitary adenomas are the most common type and benign tumours arising from hormone 
expressing cells in the anterior pituitary gland. They account for 10% to 15% of all intracranial 
masses [1,2,3,4]. No epidemiologic data found to delineate prevalence-incidence of pituitary 
adenoma in Indonesia. Yet, study from University of Indonesia estimates incidence of pituitary 
adenomas accounts at approximately 2:100.000 lives  (0.2%) [10,11]. 
Pituitary adenomas are broadly categorised as "functioning" (hormone secreting) and "non-
functioning" (non-secreting) adenomas. They can be further classified by cell type and size. 
Functional adenomas are more common and tend to present earlier, in younger patients, with 
symptoms or signs of hormone excess (eg, hyperprolactinaemia). In contrast, non-functioning 
adenomas are clinically silent until the lesion has become large enough (usually >1 cm) to have 
mass effect [1,3,5]. Prolactinomas comprise 40% to 57% of all adenomas, followed by non-
functioning adenomas (28% to 37%), hormone-secreting adenomas (11% to 13%), and 
adrenocorticotropic hormone (ACTH) secreting adenomas (1% to 2%). Tumors are also 
categorized based on size. If the tumor is 10 mm or larger, it is considered a macroadenoma; if it 
is less than 10 mm, it considered a microadenoma. Microadenomas are slightly more common 
than macroadenomas (57.4% vs. 42.6%) [1,3,4]. Also, considered a giant adenomas if size 
exceeds 40 mm [12]. 
Pituitary adenomas present clinically in three ways: syndromes of hormone hypersecretion or 
deficiency; neurologic manifestations from mass effect of an expanding gland; or an incidental 
finding on imaging done for an unrelated issue [1,3,6]. Headaches are common in pituitary 
adenomas (37-70%) but are usually non-specific and often not the predominant presenting feature, 
unless in association with acromegaly or pituitary apoplexy. Headaches, which are believed to 
result from stretching of the dural sheath, are nonspecific and do not necessarily correlate with 
tumor size [3,10]. In pituitary apoplexy, headache is sudden, severe, and often associated with 
visual disturbance or ocular palsy. It occurs when there is acute hemorrhage or infarction within 
pituitary adenomas (2-12%) and can be life threatening if not treated promptly .[5] Pituitary 
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apoplexy can occur in pituitary tumors due to intratumoral hemorrhage or infarction. Risk factors 
for apoplexy include anticoagulant drugs, hormone stimulation testing, intracranial surgery, or 
dopamine agonists. However, the pathogenesis of pituitary apoplexy is largely unknown.[13] 
Neurologic symptoms are more common in non-functioning adenomas or gonadotroph adenomas 
because these tumors do not secrete sufficient hormones to cause endocrine-type symptoms, and 
their diagnosis often is delayed until presented with mass effect: the visual field defect usually 
goes unnoticed by the patient until severe and is typically a bitemporal hemianopia due to 
chiasmatic compression. If the adenoma expands laterally into the cavernous sinus, it has the 
potential to affect the cranial nerves housed there, including cranial nerves III (oculomotor), IV 
(trochlear), and VI (abducens). In contrast with headaches, visual disturbances tend to correlate 
with tumor size, tend to occur insidiously so that many patients are not aware of them until they 
are specifically tested. [1,3,6,14] 
Pituitary adenomas are often clinically silent or manifest with non-specific symptoms, which can 
lead to a delayed diagnosis. Clinical practice shows that both functioning and non-functioning 
pituitary adenomas are likely missed initially due to non-specific symptoms such as, tiredness, 
weight gain, problems with periods, libido, and erectile dysfunction. Underlying endocrine 
problems are a relatively rare cause of such symptoms in primary care, therefore the relevant 
initial examinations for pituitary adenoma (visual fields and blood tests) may not be considered. 
[5] 
A patient who presents with symptoms of hormone excess likely has a functioning adenoma. 
Evaluation can be geared toward the specific hypersecretory syndrome. Hormone deficiencies 
should also be evaluated because hypopituitarism is present in up to 30% of adenomas, and 
because of the need to address deficiencies in future treatment regimens. Consensus guidelines 
recommend obtaining an endocrine panel as an initial set of laboratory tests. This includes serum 
prolactin, insulin-like growth factor 1 (IGF-1), LH/FSH, TSH, thyroxine (T4), and an initial test 
for cortisol excess-a 24-hour urine free cortisol, a late night salivary cortisol, or a low-dose 
dexamethasone suppression test. The 24-hour urine free cortisol, late night salivary cortisol, and 
overnight dexamethasone suppression tests have similar accuracy (positive likelihood ratio [LR+] 
= 10.6, negative likelihood ratio [LR–] = – 0.16; LR+ = 8.8, LR– = 0.07; and LR+ = 16.4, LR– = 
0.06, respectively). Dexamethasone suppression and 24-hour urine free cortisol tests have the 
highest specificity (97% and 91%, respectively) and the most evidence to support their use. When 
the diagnosis remains uncertain after these initial studies, dynamic endocrine function tests should 
be performed, usually in consultation with an endocrinologist. [3] 
A higher serum prolactin level (250 μg per L [10.870 pmol per L] or more) suggests a 
prolactinoma over other causes of hyperprolactinemia (e.g. hypothyroidism, medications, non-
prolactin-secreting pituitary adenomas, pregnancy, renal failure). A serum prolactin level greater 
Journal of Endocrinology, Tropical Medicine, and Infectiouse Disease (JETROMI) Vol. 02, No. 4, 2020                        195                                                          
than 500 μg per L (21.739 pmol per L) is diagnostic for a macroprolactinoma (98% specificity), 
although only about one-third of persons with prolactinoma have levels that high (35% 
sensitivity). Non–prolactin-secreting pituitary tumors may cause moderate elevations in prolactin 
through compression of the pituitary stalk, resulting in loss of inhibition of prolactin release; this 
is termed the stalk effect [4,11,12]. If the tumor is very large (>3 cm), the very high prolactin 
levels (usually >10 000 μg/L) may rarely saturate the antibodies in some assays, leading to 
artifactually low or normal results (the "hook effect") and prolactin levels should be rerun at 1:100 
dilution to exclude this.[12] 
Rapid pituitary adenoma growth causes a sudden increase in intrasellar pressure which results in 
ischemic necrosis of various portions of the anterior pituitary gland and further damage of normal 
residual tissue, limiting the chances of hormone function recovery. ACTH deficiency reported in 
70% of cases, is the most important hormone deficiency. TSH and gonadotropin deficiency have 
also been reported in 50% and 75% of cases, respectively, but they generally become clinically 
relevant only after several months when directly caused by pituitary necrosis [7,8,9,15]. It leads 
to low production of cortisol and thyrosine, as shown in this case. Furthermore, mineralocorticoid 
levels are normal in ACTH-deficient patients. Hyponatremia is a direct consequence of 
glucocorticoid deficiency, and is related to inappropriate antidiuretics resulting from 
nonsuppressible arginin vaspressin release and, probably, to a direct renal water excretion defect, 
both being consequences of cortisol deficiency. [8,9,15] 
Increased use and sensitivity of computed tomography (CT) and magnetic resonance imaging 
(MRI) have identified many pituitary lesions that otherwise might not have been detected. 
Autopsy and radiology studies suggest that between 5% and 20% of all pituitary adenomas may 
be unsuspected or found incidentally.[1,6,10,16] If a pituitary mass is suspected, MRI is the best 
initial imaging study. MRI is 61% to 72% sensitive and 88% to 90% specific for sellar masses. 
The study should be done with and without gadolinium enhancement. CT is limited by its inability 
to precisely image the optic chiasm. If an MRI is contraindicated or unavailable, CT done with 
thin sections (1.5 mm or less) and in a coronal plane will improve imaging of the pituitary region. 
There are three primary treatment goals for pituitary adenomas: reducing hormone hypersecretion 
and its clinical manifestations; decreasing tumor size to improve symptoms of mass effect; and 
correcting hormone deficiencies. [3] 
MRI is the imaging test of choice for diagnosis because it detects 90% of the cases (CT scan 
detetcts 20% only).[7] As hyperdensity in the subacute and chronic phases of hemorrhage fades, 
CT sensitivity to diagnose PA diminishes and the lesion could be misdiagnosed as an abscess or 
cystic degeneration. In contrast, CT is superior during the first three hours after apoplexy. Usually 
in the first week, an isointensity on T1-weighted scans and a hypointensity on T2-weighted 
images can be observed with MRI. Subacutely, there is focal or heterogeneous increased signal 
on T1-weighted scans, and a progressive increase in signal on T2-weighted images. In the chronic 
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phase, there is signal increase in both T1 and T2 weighted images. Necrosis imaging can be 
detected as hypodensity by CT and hypointense on T1 and hyperintense on T2 on MRI. [9] 
Nonfunctioning pituitary macroadenoma treatment can involve single or combinations of surgical 
intervention, radiotherapy or pharmacological treatment. For those adenomas larger than 1 cm 
(the majority), after excluding hormone deficiencies, it is common to proceed to surgical 
management. Pharmacological treatment of the Nonfunctioning pituitary macroadenoma itself is 
typically unsuccessful. Medical management is frequently based around regular follow-up, 
monitoring of visual problems, and secondary hormone deficiencies .[17] The patients require 
hydrocortisone replacement, an adrenal crisis (acute cortisol insufficiency) can ensue during times 
of illness which can be life-threatening and must be managed.  
As regards treatment due to hypocortisolism, this patient in this case received prednisone 10-0-5 
mg. In fact, glucocorticoid replacement therapy is the most effective medical intervention because 
secondary adrenal insufficiency is the most significant risk factor for death and complication. The 
use of hydrocortisone 100-200 mg IV, followed by a continuous IV infusion of 2-4 mg per houris 
recommended. The use of dexamethasone is not recommended; however, it could be useful in 
decreasing edema as a nonsurgical approach to pituitary apoplexy. [7, 8,9,15] Because acute 
secondary adrenal insufficiency is very frequent in patients with apoplexy, empiric parenteral 
corticosteroid supplementation should be given to all patients with signs of pituitary apoplexy, 
without waiting for diagnostic confirmation [15]. Overall, patients suffering from pituitary 
apoplexy will require glucocorticoids (60-80%), thyroid hormone (50-60%), and desmopressin 
(10-25%). [7,15] 
Therefore, it is advised that MRI should be repeated annually in these patients. The operation or 
radiotherapy should be contemplated only when the tumor regrowth is confirmed, except where 
the adenomatous residue is tebal dan dekat to the optic nerves/chiasm.[18] Whether 
Nonfunctioning pituitary macroadenoma are associated with an increased mortality or reduced 
lifespan is still unknown.[19] 
4 Conclusion 
We have reported a case of newly diagnosed patient with nonfunctioning pituitary 
macroadenoma. Medical management is frequently based around regular follow-up, monitoring 
of visual problems and secondary hormone deficiencies. The patients require hydrocortisone, 
thyroid hormone replacement, monitoring of visual problems. 
REFERENCES 
[1] Hidayat, Muhammad, “Adenoma Hipofisis,” Tinjauan Pustaka Jurnal FK Unand, vol. 38, 
Nomor 2, Agustus 2015.  
Journal of Endocrinology, Tropical Medicine, and Infectiouse Disease (JETROMI) Vol. 02, No. 4, 2020                        197                                                          
[2] H. Elizabeth, G. Wira, “Manifestasi Disfungsi Beberapa Hormon dari Seorang Penderita 
dengan Riwayat Adenoma Hipofisis,” Laporan Kasus J Peny Dalam, vol. 8 no.1, Januari 
2007.  
[3] L. Marcy, K. Linda, C. Samya. “Pituitary Adenomas: An Overview,” American Family 
Physician Website. 2013. http://www.aafp.org/afp/2013/0901/p319-s1.html. 
[4] A. Khalid, B. Samia, A. Faisal, A. Muneera, K. Patan, “The epideniology of pituitary 
adenomas in a community-based hospital: a retrospective single center study in Saudi 
Arabia,” Ann Saudi Med, 36(5): 341-5. September 2016, doi: 10.5144/0256-4947. 2016. 
[5] P. Aparna, L. Laurence, W. John, “Pituitary Adenomas,” BMJ, June 2019. doi: 
10.1136/bmj.I2091 
[6] M. Moises, M. Virgilio, S. Latife, C. Dalia, “Clinically non-functioning pituitary 
adenomas: Pathogenic, diagnostic and therapeutic aspects,” Endocrinologia, Diabetes y 
Nutricion, Elsevier, July 2017. http://dx.doi.org/10.1016/j.endinu.2017.05.009 
[7] Pinto-Valdivia M, et al. Apoplejía pituitaria. A propósito de un caso. Endocrinol Nutr 
60:37-47. 2013 
[8] Albant A, ferrati F, Angileri FF, Esposito F, Granata F, et al. Multidisciplinary management 
of pituitary apoplexy. Int J Endrocrinol.;1-11.2016 
http://dx.doi.org/10.1155/2016/7951536 
[9] Glezer A, Branstein MD. Pituitary apoplexy: pathophysiology, diagnosis and management. 
Arch Endocrinol Metab 59(3):259-65. 2015. DOI: 10.1590/2359-3997000000047 
[10] C. Rahmat, S. Pradana, D. Budiman. “Gambaran Klinis dan Proporsi Hipotiroidisme 
Sekunder pada Pasien Adenoma Hipofisis di Rumah Sakit Cipto Mangunkusumo,” Artikel 
Penelitian J Indon Med Assoc 68(6), Juni 2018.  
[11] G. Ni Putu, H. Hanik, “Laporan Kasus: Perbaikan Kadar Prolaktin pada Makroadenoma 
Hipofisis dengan Terapi Bromokriptin dan EETA,” Jurnal Farmasi Klinik Indonesia, 9(3) 
hal. 237-44. 2020 
[12] M. Mark, “Diagnosis and Treatment of Pituitary Adenomas A Review,” Clinical Review 
& Education, JAMA Review, vol. 317, no.5. February 2017. 
DOI: 10.1001/jama.2016.19699 
[13] Melmed ,Shlomo, “Pituitary Tumors,” HHS Public Access, Author Manuscript, vol.44, no. 
1, p:1-9, March 2016, doi: 10.1016/j.ecl.2014.11.004. 
[14] Herse, Peter. “Pituitary macroadenoma: a case report and review,” Clinical and 
experimental Optometry, vol. 97, p:125-132, May 2013. DOI:10.1111/cxo.12099 
[15] Briet C, Salenave S, Bonneville JF, Laws ER, Chanson P. Pituitary Apoplexy. Endocr Rev 
vol. 36, no.6, p:622-45. 2015.   doi: 10.1210/er.2015-1042 
[16] M. Bradley, W. Robert, C. Ryan, “Demographic Differences in Incidence for Pituitary 
Adenoma,” NIH Public Access, vol. 14, no.1, p:23-30, March 2011. doi:10.1007/s11102-
010-0253-4. 
[17] Saunders S, Vora JP. Endocrine evaluation of pituitary tumours. Br J Neurosurg vol.22, 
no.4, p:602–8. 2008 
[18] Chen Y, Wang CD, Su ZP, Chen YX, Cai L, Zhuge QC, Wu ZB. Natural history of 
postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. 
Neuroendocrinology vol.96, p:333–42. 2012 
[19] Ellegala DB, Alden TD, Couture DE, Vance ML, Maartens NF, Laws Jr ER.  Anemia, 
testosterone, and pituitary adenoma in men. J Neurosurg vol.98, no.5, p:974–7. 2003 
 
 
